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ABSTRACT 
 
 
 
Northern, William Isaac.  M.S., Department of Biological Sciences, Wright State 
University, 2007.  Discovery of New Antimicrobial Agents Using Combinatorial 
Chemistry 
 
 
Combinatorial chemistry has become an important aspect of medicinal research due to its 
flexibility and the ability to produce large numbers of potential therapeutic agents.  Once 
compounds are made, they must be screened to determine if there is any biological 
activity.  This research project focused on developing a screening method for chemical 
agents produced by a graduate student in the chemistry department at Wright State 
University.  After an acceptable screening method was found, the goal of the project was 
to determine if compounds produced had either antibacterial activity, antifungal activity, 
or both.  Seven compounds exhibited biological activity.  Two of these compounds had 
activity against all organisms tested.  Five compounds had activity against only 
Staphylococcus aureus.  Also, initial toxicity studies were performed on the two 
compounds that had activity against both bacteria and fungi.  The toxicity was detected 
by cytopathic effect (CPE) noted in human and monkey cell lines.  One compound 
demonstrated severe toxicity while the other compound demonstrated slight toxicity.  
Additional research, including animal safety studies, will be required to determine if 
these compounds are viable prospects for development into antimicrobial agents.  This 
research confirmed that it is possible to use combinatorial methods to produce agents.  
However, the ability to produce antimicrobial compounds is only a small part of 
producing a useful drug.   
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INTRODUCTION 
 
 
Importance of Finding New Antimicrobials 
 
 The use of antimicrobial agents is critical to successful treatment of infectious 
diseases.  Although there are numerous classes of drugs that are routinely used to treat 
infections in humans, there are several reasons why the discovery and development of 
new antimicrobial agents are important.   Over the past decade there has been an 
increased development of resistance in organisms that are typical pathogens in humans.  
These include methicillin/oxacillin-resistant Staphylococcus aureus (1,2), vancomycin-
resistant and intermediate Staphylococcus aureus (3,4), vancomycin-resistant 
Enterococcus (2,5), gram-neagtive bacilli that produce extended spectrum beta-
lactamases (6,7), carbapenem-resistant Klebsiella pneumoniae (8), and Pseudomonas and 
Acinetobacter (9) strains that are resistant to all antibiotics that are typically used for 
treatment.  Figures 1 and 2 show a graphical representation of the rise in resistance for 
two common pathogenic organisms that are isolated in clinical laboratories (10).  This 
increased resistance has limited the selection of antimicrobials that may be used to treat 
specific organisms.   
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Figure 1:  Percent resistance in selected antibiotics in Staphylococcus aureus at 
CompuNet Clinical Lab, Moraine, Ohio, 1996 to 2006 (10).  
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Figure 2:  Percent resistance in selected antibiotics in Acinetobacter baumanii at 
CompuNet Clinical Lab, Moraine, Ohio, 1996 to 2006 (10). 
 
 New antimicrobials are also needed for certain groups of organisms.  Very limited 
numbers of antimicrobials are available to treat infections caused by fungi and 
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mycobacteria.  Infections with these organisms continue to be a major concern.  
Chemotherapy for cancer treatment, immunosuppressive drugs for treatment of 
autoimmune diseases and organ transplant recipients, and infections (such as AIDS) that 
alter the effectiveness of the host immune system render individuals at high risk for 
fungal infections and certain mycobacterial infections.  Often these infections are caused 
by environmental organisms that would not typically cause disease in a normal host.  
There are increased numbers of reports of multi-drug resistant mycobacteria in the United 
States and throughout the world (11).  Another complicating factor that reduces the 
effectiveness of treatment of these organisms is non-compliance in completing treatment 
regimens.  Extended length of treatment (sometimes up to one year) and adverse side 
effects of the drugs used for treatment contribute to the lack of compliance.  
 Although many infectious diseases have been known for thousands of years, over 
the past 30 years a number of new infectious diseases have been discovered.  Some 
examples include Lyme Disease caused by Borrelia burgdorferi, Legionnaires’ Disease 
caused by Legionella pneumophila, peptic ulcers caused by Helicobacter pylori, 
antibiotic associated diarrhea caused by Clostridium difficile, and AIDS caused by 
Human Immunodifficiency Virus.  In addition, microorganisms are constantly changing, 
finding new places to live and new ways to survive, and adapting to new situations.  
During this process, harmless organisms may turn deadly or deadly strains may move 
from their normal host to humans.  With the continuing discovery of new infectious 
diseases and the development of new disease processes of existing pathogens (i.e., 
necrotizing fasciitis caused by Streptococcus pyogenes), it is important to continue to find 
anti-infective agents that can be used to treat these infections (12,13). 
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 Development of novel classes of drugs, drugs with fewer side effects, and drugs 
with shorter lengths of treatment are key in continuing the fight against infectious 
disease.   
 
Historical Perspective 
 
 In the early 1900’s, a number of investigators were performing research on 
microorganisms.  Paul Ehrlich was interested in distinguishing bacteria from tissue in 
histopathological slides.  He noted that some dyes were taken up by human or animal 
cells but not by others.  He also noted that there were dyes that were taken up by bacteria 
but not human cells and that there was a variation of up-take amongst bacteria.  A Danish 
microbiologist, Hans Christian Gram, had already demonstrated that bacteria could be 
divided into two groups based upon their up-take of various dyes.   (His research is the 
basis for the gram stain that is used in microbiology laboratories today.)  Paul Ehrlich 
explained that the selective binding of the dyes was due to differences in the cell surfaces 
and felt that this property might be exploited.  He postulated that if a dye could bind to a 
bacterial cell but not human cells and could kill the bacterial cell, an infection could be 
eradicated.  He tested thousands of dyes to find one that met these criteria and in 1909 
synthesized arsphenamine, a drug that could destroy the syphilis-causing organism 
Treponema pallidum.   Unfortunately this drug compound had severe side effects and 
resulted in the death of numerous patients (14,15). 
 In 1915, Gerhard Domagk was an infantryman in the German military.  He was 
wounded and sent to a hospital in Berlin.  During his recuperation he trained as a medical 
assistant and was horrified when he recognized that many deaths in the military hospital 
did not come from direct war injuries but rather from the festering of wounds.  This 
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experience convinced him that he should pursue a career in medicine.  In 1932, he was 
working in an experimental pathological laboratory for a German chemical company I.G. 
Frabenindustrie that manufactured dyes for the textile industry.  He was given the 
freedom to research whatever he thought was important and he chose to look for a 
compound that would selectively kill streptococci.   He tested hundred of substances 
before finding a red dye called prontosil.  He discovered that this compound protected 
mice from infections with streptococci.  In 1936 it was discovered that a smaller, more 
effective compound known as sulfanilamide (a sulphonamide) was the active agent in 
prontosil.  A demonstration for a group of German army surgeons proved to them that 
sulphonamides were effective in treating gangrenous wounds.  Sulphonamide was soon 
packaged into small containers and became a standard issue for immediate disinfection of 
battle wounds during World War II (14).  
 In 1928, Alexander Fleming was working at St. Mary’s Hospital in London 
researching agents that could be used to fight bacterial infections.  Due to a serendipitous 
event, he discovered that staphylococcus would not grow around a mold that was 
growing on his culture plate.  The mold was identified as Penicillium notatum.  Fleming 
named the substance that was inhibiting the staphylococcus “penicillin”.  However, he 
was unable to purify it, nor did he realize the potential for use in treating infections.  
About ten years later two investigators, Ernest Chain and Howard Florey, tried to 
stabilize and purify the “penicillin”.  They were unable to produce enough of the purified 
substance to test its efficacy as an antimicrobial agent.  Chain decided to inject an extract 
of the mold into healthy mice that were experimentally infected with streptococci.  He 
noted that the infection was halted and the mice remained healthy after the experimental 
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treatment with the mold extract.  In 1940, enough purified penicillin was produced to test 
it on mice.  In these experiments, two groups of mice were infected with streptococci.   
One group was injected with penicillin while the other group was not treated.  All of the 
mice that received penicillin survived while all the mice that were not treated died.  Later 
studies showed that penicillin could safely be used to treat humans and was used to treat 
soldiers during World War II (12,14). 
 The discovery of penicillin led to the recognition that microbes produce 
substances that inhibit each other, setting off decades of intensive screening of bacterial 
cultures for new antibiotic classes.  This resulted in the discovery and successful 
development of penicillins, cephalosporins, tetracyclines, aminoglycosides, rifamycins, 
glycopeptides and macrolide antibiotics (16). 
 
Sources of New Antibiotics 
 
 Over the past 20 years, two general approaches have been taken in antimicrobial 
drug discovery.  The first involves modification of existing antibiotics.  The second is 
aimed at identifying new compounds that inhibit microorganisms that are not targeted by 
existing agents.  Today the main sources for new drugs are natural products, synthetic 
products, existing drugs, and genomics (17).  Each of these will be discussed in detail. 
 
Natural products 
 
 The discovery of penicillin gave rise to the concept of seeking naturally occurring 
drugs (17).  This was true for anti-infectives as well as other types of drugs.  The 
discovery of vineristine and vinblastine in 1963 by R.L.Noble and its successful use by 
Eli Lilly launched the pharmaceutical industry into the search for natural products for 
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treatment of various cancers.  Other drugs that started as natural products include 
avermectin (antihelmenthic), cyclosporine and FK-506 (immunosuppression), mevinolin 
and compactin (cholesterol-lowering), and taxol and comptothecin (anticancer) and have 
revolutionized therapeutic areas in medicine (18).  Between one quarter and one third of 
all currently available drugs were derived from natural products (19). 
 In the anti-infective area, treatment is dominated by natural products and natural 
product analogs such as penicillins, cephalosporins, and vancomycin (20).  These natural 
products can come from a number of different sources:  bacteria, fungi, plants, and 
marine environments. 
 
Bacteria and Fungi: 
 
 Natural products with antibiotic activity that come from bacteria or fungi are 
almost always products of secondary metabolic pathways.  These pathways are not 
required for primary, life-sustaining functions of metabolism.  When antibiotic-producing 
organisms face competition in their environment, they turn on genes that encode the 
antibiotic molecules and use them to wage chemical war on their neighbors.  They then 
have a selective advantage for growth, including the nutrients from their dying neighbors 
(16).  Organisms which cause human infections do not survive well in soil because they 
are destroyed by soil-inhabiting organisms.  As a result, extensive soil-screening 
programs have resulted in the discovery of drugs such as streptomycin, chloramphenicol, 
chlortetracycline, erythromycin, neomycin, bacitracin, and polymixin (17).  
 Many of the drugs listed above were isolated from actinomycete species.  
Actinomycetes are filamentous gram-positive bacilli that make up a large portion of soil 
microbes.  When these drugs were originally discovered, broth cultures of the 
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actinomycetes were grown and then tested for antimicrobial activity using whole-cell 
screening assays.  Currently, many species of actinomycetes are non-cultivable and other 
means must be used to further discover new or novel antimicrobials.  A company in 
Cambridge, Massachusetts, (NovoBiotic Pharmaceuticals) is making progress in learning 
how to grow actinomycetes that will not grow on standard laboratory media.  Their 
progress, along with the use of genomic and combinatorial chemistry (to be discussed 
later) make actinomycetes a continuing potential source of clinically relevant antibiotics 
(21,22). 
 
Marine Environments:    
 
 Chemical defenses employed by many organisms have proven to be available 
sources of novel molecules providing lead compounds for drug discovery.  Among the 
least-explored of the planet’s chemically defended organisms are the invertebrates, algae, 
fungi, and bacteria of the marine environment.  There are greater than 2,000,000 marine 
animals and microorganism species available for investigation.  The marine environment 
contains about half of the total global species and contains a biodiversity as extensive as 
all the world’s rain forests combined.  This biological diversity has resulted in a vast 
array of chemical diversity.  Many marine organisms have a sedentary life style and 
require a chemical means of defense.  As a result, they have the ability to produce or 
obtain toxic compounds to deter predators and keep competitors at bay.  Bioprospecting 
in the marine environment has only started relatively recently but has already yielded 
thousands of novel compounds.  One group studying the marine environment during the 
past 25 years has isolated over 10,000 compounds from marine invertebrates: algae, 
bacteria, fungi, and protozoa.  Less than 0.5% of marine animals have been examined to 
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determine if they produce compounds that might be used as therapeutic agents against 
infectious diseases.  Improved underwater life-support systems have provided marine 
scientists new mechanisms for collecting from unexplored regions and depths (23,24).  
 Marine actinomycetes are a group of organisms that have demonstrated great 
promise as a source of potential new drugs.  These organisms account for 10% of marine 
snow (dead or dying animals and plants such as plankton, diatoms, fecal matter, sand, 
soot and other inorganic dust) that settles to the ocean floor.  Marine actinomycetes 
exhibit very different 16S rRNA sequences compared to their terrestrial counterparts.  As 
a result, marine actinomycetes produce novel metabolites that may be biologically active 
and a potential source of new anti-infective drugs (25).   
 One of the concerns of bioprospecting in the marine environment is the 
complexity of marine molecules.  Because of this complexity, it is often difficult or 
impossible to manufacture the molecules in the large-scale production that is required 
when selling a drug.  However, studies support the idea that most bioactive compounds 
isolated from marine invertebrates are the result of biosynthesis of the active compounds 
by microorganisms.  Further studies allowing isolation of the particular microorganisms 
that are responsible for making the active compounds may reduce or eliminate this 
concern (26). 
 
Plants: 
 
 Plants produce substances that help protect them from microorganisms, 
herbivores, competing plants, and aide in reproduction.  They also produce chemicals for 
offensive chemical warfare targeting cell proliferation of pathogens.  These chemicals 
may have general or specific activity against key target sites in bacteria, fungi, viruses, or 
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neoplastic diseases (18).  It is estimated that more than 250,000 species of higher plants 
exist and that only a fraction have been investigated to characterize the chemical 
constituents for biological effects (19). 
 When plants are being examined, a successful drug discovery program requires 
several key components.  It is necessary to have a continuing collection of new and 
preferably unique plants at a rate sufficient to generate several good leads per year.  
There must be a selective and effective set of bioassays to detect which plant extracts 
contain bioactive constituents.  An effective mechanism for screening out compounds 
that have already been tested or otherwise uninteresting will allow drug companies to 
concentrate their work on compounds that have a high potential for becoming a 
marketable drug.  An efficient fractionation and structure determination program will 
facilitate the isolation and identification of bioactive products (20). 
 When collecting samples, the goal is to obtain maximum chemodiversity and 
therapeutically useful biological activity within a minimum number of collected samples.  
Samples may be collected randomly or folklore information on medicinal plants may be 
used.  Since many of the samples collected are found in remote areas of the world (i.e. 
rain forests), it is beneficial to collaborate with the endogenous people for collection.  
These people possess a vast knowledge of the plants in their part of the world.   In 
particular, shamans or “witch doctors” use these plants in tribal medicine and have an 
understanding of how plants and other substances may be used to treat illnesses (20).   
 Some of the key decisions in sampling include:  what quantity to collect, and how 
to store and process samples (19).  Plant samples may be taken from roots, bark, twigs, 
and leaves.  They are then dried and sent to the lab for extraction.  If collaboration with 
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endogenous people is possible, the plants may be from “gardens” of tribal shamans or 
healers.  Information should be collected about each plant.  This includes:  various 
medicinal uses, area where found, part of plant used for medicinal purposes, habitat, soil, 
visibility, abundance, how medicine is prepared by shaman, local name of plant, dosage, 
method of application, and side effects (20). 
 After the samples are tested, plants with bioactivity are recollected to confirm 
initial results.  An extract from the plant is then fractionated in an effort to isolate and 
characterize the active entity (20).  To fractionate samples, they are dried and 
reconstituted in solvents (27).  Ethyl acetate and methanol may be used for this extraction 
(20).   Initial fractionation of crude extracts can be done by countercurrent 
chromatography.  This separation method is one of the least destructive of the compound 
of interest (27).  Fractions are isolated and put in separate tubes and tested for biological 
activity.  Fractions may be considerably pure and isolated in reasonable quantities after a 
single chromatographic step (27). 
 
Testing Compounds 
 
 The goal of testing natural products is to identify compounds with selective and 
specific biological effects on contemporary and relevant disease targets.  It is also 
important to ensure in vivo efficacy while at the same time preventing toxicity (19). 
 The most efficient primary assays used for screening compounds have a high 
through-put design to detect samples with the most promise for yielding interesting 
compounds (i.e. screening out the majority of low or moderate activity or non-selective 
activity).  This is often based on identifying compounds that inhibited growth of target 
pathogens.  In addition, the use of subcelluar assays and whole-cell assays make it less 
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likely to miss novel mechanisms on the primary screen (19).  The subcellular and whole-
cell assays are used to detect compounds that affect enzymes, cell receptors, ion channels, 
and nucleic acid replication in microorganisms.  One of the advantages of subcellular 
assays is that they can yield a large number of potentially active compounds.  However, 
many of the active compounds may not demonstrate activity when tested in whole-cell 
assays.  Whole-cell assays simulate the natural milieu in which the targets reside and are 
often more indicative of the way molecular targets react in their natural state (28,29). 
 Samples found to have biological activity are subjected to “dereplication”.  This is 
the process of checking to see if a compound (or similar compounds) has been tested 
before.  Samples that have not been tested before are subjected to additional studies to 
provide an early indication of novel chemotypes responsible for the activity.   
            Secondary assays are designed to corroborate and quantitate activity observed in 
the primary assay, to establish spectrum of activity, to provide insight into the mode of 
action, and to predict in vivo pharmaceutical properties.  Criteria are necessary for 
determining the relative importance of lead compounds and if there is evidence to suggest 
a novel mechanism of action.  This may be accomplished by testing to see if the 
compound is active against strains resistant to other known agents, if it inhibits known 
targets (i.e. cell wall biosynthesis), or how it influences general biochemical pathways 
(i.e. protein or nucleic acid synthesis).  There are a number of assays that have been 
described that may be used to help make these determinations (30,31,32,33).  Compounds 
with novel activity should be followed up with more extensive studies to determine 
molecular site of action (19). 
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 A number or methods may be used to elucidate the structure.  These include:  
liquid chromatography, mass spectrometry (MS), nuclear magnetic resonance (NMR), 
infared spectrometry (IR), and ultra-violet (UV) absorption.   
 Liquid chromatography and MS are used to study crude extracts and multi-
component fractions for the presence of specific bioactive compounds or compound 
types.  These methods are used as part of the dereplication process to help identify known 
classes of compounds when looking for novel bioactive compounds.  MS is used in 
conjunction with NMR spectroscopy to allow determination of the molecular formula of 
a compound.  Since nitrogen is found in many natural products, mass spectral data can be 
used to determine the position of nitrogen and allow elucidation and confirmation of 
structures (27).  This data is then compared to a data base of compounds that have 
already been tested (34). 
 NMR is the best method to use for non-crytalline compounds.  It allows fragments 
of compounds to be combined into complete molecules and may be used to definitively 
identify metabolites (23).  Use of molecular weight and UV absorbance data with Berdy 
Bioactive Natural Products Database allows rapid identification of compounds.  The 
identification is then confirmed by NMR (27).   IR yields information about functional 
groups. 
 Results of bioassays and structure elucidation may indicate that an isolated 
product is not an effective drug.  However, it may have a novel molecule.  In such cases 
chemical modification of the natural product structure can often yield clinically useful 
drugs.  (To be discussed later.)  Appropriate and selective bioassays should be used to 
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screen potential drugs.  “Hit rates” may be small, requiring thousands of compounds to be 
screened (20).   
 
Existing Antibiotics 
 
 In the past, natural products have been the main source of new molecules that are 
developed into medically useful antimicrobials.  However, after the first antimicrobial 
agents were discovered and routinely used to successfully treat infections, it became 
evident that these drugs had limitations.  By studying the chemical properties of each 
drug and its limitations, modifications were made that resulted in new drugs that had 
improved characteristics and decreased limitations when compared to the original drugs. 
 Some drugs have toxic side effects.  Amphotericin B causes renal toxicity while 
fluoroquinolones cause phototoxicity.  A lipophilic formulation reduced the nephrotoxic 
effects of amphotericin B.  Substitutions at a key position on the quinolone molecule 
eliminated this toxicity in newer fluoroquinolones (13,35). 
 Alterations in dosing regimens may show substantial improvement in patient 
treatment.  Reducing the frequency of doses taken each day and the number of days that 
the drug is required to be taken greatly increases the chance that patients will be 
compliant in correctly taking their medicine.  For example, the half-life of the macrolide 
erythromycin is 2-3 hours.  However, the half-life of a newer macrolide, azithromycin, is 
40-68 hours.  This difference allows azithromycin to be taken once per day and is an 
improvement when compared to multiples doses per day required for erythromycin 
(36,37).   Pharmacological changes in the antimicrobial molecule can affect the route of 
administration of the drug, such as a drug that is given intravenously or intramuscularly 
being altered to allow it to be administered orally.  The route of administration can    
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ensure the antimicrobial reaches the site of infection.  An example of a drug whose    
route of administration was modified to ensure that the drug reached the site of infection 
is the inhaled formulation of tobramycin.  This is used by cystic fibrosis patients to get 
drugs directly to the lungs where infections typically occur (13,38). 
 Development of resistance is a major concern with any antibiotic.  Modifications 
of the molecule that protect the antimicrobial agent from resistance formation include 
combining complementary mechanisms of action in one drug, molecular hybrids or 
chimera, and chemical substitutions of functional chemical groups on the drug.  
Tigecycline is an example of a drug that has complementary mechanisms of action.  It not 
only possesses the same action as tetracycline of inhibiting protein synthesis in the 
ribosomes but also evades a common resistance mechanism for tetracycline known as an 
efflux pump.  Efflux pumps are transmembrane proteins that actively export the 
antimicrobial agent out of the microbial cell, often against a concentration gradient.  
Steric hindrance prevents extrusion of the tigecycline molecule from the cell due to a 
bulky substitution at a key position on the molecule that impedes its elimination from the 
bacterial cell.  Combinations of a fluoroquinolone with a beta-lactam and a 
fluoroquinolone with an oxazolidinone molecule are examples of molecular hybrids 
(39,40).  Although these combination drugs are not currently in use, they serve as models 
for chimeric drugs.  Substitution of chemical groups on a known antibiotic has resulted in 
the development of numerous new drugs and will be discussed in detail (13,38,41). 
 Advances in understanding of bacterial physiology has led to the development of 
“structure-activity relationships” (SAR) that are used to direct the chemical modification 
of antibiotics to improve their activity.  This led to discovery of new antibiotics that are 
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active against organisms that have acquired resistance.  The SAR identifies important 
regions of the compounds that are necessary for biological activity and those regions that 
can be changed to improve the drug-like properties of the compounds (42).  The 
approaches used to develop SAR usually rely on determining which substitution made on 
a particular molecule will translate to improved antimicrobial activity.  An understanding 
of resistance mechanisms can play a major role in developing SAR.  For example, if the 
compound under study is an aminoglycoside, knowledge of enzymes that can chemically 
modify aminoglycosides and make them inactive is important in designing new agents 
that might avoid such modifications (38). 
 A clear example of the importance of relationships between antibiotic structure 
and biological activity is in the development of cefoxitin from cephamycin C.  
Cephamycin C had an advantage over the classical cephalosporins because it contained a 
methoxy group in a key location on the beta-lactam ring that provided resistance to 
hydrolysis by beta-lactamases.  In addition, on the same carbon atom that contained the 
methoxy group, a thienyl acetyl group was substituted for an alpha-amino-adipic acid 
moiety (See Figure 3).  This substitution broadened the spectrum of cefoxitin compared 
to cephamycin C.  This increased the activity of cefoxitin against gram-negative 
organisms and also gave it activity against gram-positive organisms (38).  With the 
understanding that the methoxy group of cefoxitin conferred beta-lactam stability, efforts 
were taken to find other derivations with even greater stability.  Using the unsubstituted 
compounds as the standard, it was found that any group at the seventh position (the 
carbon where the above substitutions were made) larger than the methyl group conferred 
enhanced stability to hydrolysis of the beta-lactam ring.  It is hypothesized that 
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substitutions at this position sterically block the beta-lactam bond from attack by the 
enzyme.  Substitution at this carbon decrease stability of some other cephalosporins (such 
as cefuroxime, cefamandole, and cephapirin) that have been shown to be less potent than 
the original molecule.  This decrease is associated with a decreased affinity of the 
substituted analogs for penicillin binding proteins (PBP) (38).  PBP’s are natural proteins 
that are involved in the synthesis of the cell wall of bacteria, bind to the bottom of the β-
lactam portion of β-lactam antibiotics, and are responsible for development of resistance 
when they are altered (43).  The results of such structure-activity studies with cefoxitn 
illustrate how making changes in an active molecule can translate into major clinical 
benefits such as lower susceptibility to inactivation (38). 
 
 
Cephamycin C 
 
Cefoxitin 
Figure 3.  Chemical structures of Cephamycin C and Cefoxitin.  The methoxy group at 
the seventh carbon position is indicated by “MeO”.  The thienyl acetyl group is to the left 
of the line in the cefoxitin diagram (44). 
 
 Another example is naturally occurring monobactams which demonstrated 
antibacterial activity that was limited to gram-negative organisms.  Competitive binding 
studies indicated that this limited spectrum resulted from poor affinity of the monobactam 
for the PBP of gram-positive organisms.  Attempts were made to broaden the spectrum of 
naturally occurring compounds by making substitutions around the monobactem nucleus. 
Adding an aminothiazole oxime side chain conferred high affinity to PBP (See Figure 4).  
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This improved its activity against Pseudomonas aeruginosa (38).  Aztreonam is the only 
example of a monobactam that is used as an antimicrobial agent (45). 
                 
 
 
Figure 4.  Structure of aztreonam.  (a.)  Aminothiazole oxime side chain.  (b.)  
Monobactam nucleus (45). 
 
 SAR studies are also being used to determine which portions of molecules are 
toxic and to see if modifications of this portion will allow the production of an active 
non-toxic antimicrobial.  An example of this is phototoxicity induced by 
fluoroquinolones (13).  Studies by a team in Japan have shown that substitution of the 
carbon at position eight by a fluorine atom is one of the causes of toxicity (See Figure 5).  
If a methoxyl group (-OCH3) is at that position, the phototoxicity is reduced (35). 
 
 
 
19  
 
Figure 5.  Basic structure of a quinolone.  R8 = Carbon 8.  Substitutions at this site can 
determine the presence or absence of phototoxicity (46). 
 
 Routinely used antimicrobials are not the only source for lead compounds when 
developing new antimicrobials from existing drugs.  Another avenue is to use veterinary 
and agricultural antimicrobial compounds as starting points.  Linezolid was originally 
used to treat tomato infections due to Agrobacterium tumefaciens.  Another example of 
other sources for new compounds is the modification of proton pump inhibitors (used to 
treat peptic ulcers) which allowed the synthesis of compounds active against 
Helicobacter pylori.  Some drugs are rediscovered several decades after they are 
originally described.  Some aminoglycosides that were active only against gram-positive 
organisms and not developed due to lack of medical need are being revived as potential 
treatment for methacillin-resistant Staphylococcus aureus (13). 
 
Genomics 
 
 The first complete bacterial genome was published for Haemophilus influenzae in 
1995.  Since then many other bacterial genomes have been completed and are available 
for use in antimicrobial research (42).  As a result of this increased knowledge, the drug 
discovery paradigm for some researchers has shifted away from finding compounds 
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against whole cells to identifying compounds that are active against selected protein 
targets (47). 
 Knowing the sequence of the microbial genome has allowed scientists to observe 
similarities and differences in the genetic makeup of various bacterial species.  Many 
genes that have been sequenced are highly conserved (or shared among numerous 
bacterial species).  It is postulated that these genes and the proteins for which they encode 
are most probably essential for life (48).  Essential genes make up about 25% of the 
bacterial genome (47) and are responsible for DNA replication, transcription and protein 
synthesis, lipid biosynthesis, and cell wall assembly (48).  Since these genes are 
responsible for basic life functions, substances that could block their activity could be 
developed into highly effective and broad spectrum antimicrobial agents.  
 With the completion of sequencing the human genome in 2003, it was possible to 
compare microbial genomes with the human genome to identify microbial genes that do 
not have comparable human genes (42,49).  When eliminating genes found in the human 
genome and other eukaryotic cells, it is estimated that about 10% of a microbe’s genes 
are unique and are prime targets for development of new and novel antimicrobial agents 
(47). 
 Once a gene is identified as a potential target for a new antimicrobial agent, 
assignment and confirmation of the gene function is crucial for genome-based drug 
discovery.  The structure of proteins encoded by a particular gene can be determined by 
inserting the gene into an Escherichia coli strain.  The  Escherichia coli will then produce 
large quantities of the protein that may be used for screening for antimicrobial activity or 
allow characterization to occur (42).  This characterization can be accomplished by 
 
21  
performing microarrays, protein-to-protein interaction studies, and mutagenesis (or 
“knock-out”) studies.  Microarrays can be used to monitor bacterial gene expression in 
response to environmental conditions (50).  In a gene knockout study, the function of the 
gene is determined by altering the gene so it is non-functional.  This may be 
accomplished by inserting a foreign sequence to disrupt the gene (51).  If a particular 
cellular product or function is not found when the gene is “knocked-out”, the gene’s 
function is confirmed (48).   
 Comparing genomes of pathogens and non-pathogens might detect virulence 
factors and allow drugs to be developed that may not kill the organism but inactivate a 
virulence factor.  Many differences between strains of a species are due to acquisition or 
deletion of DNA segments.  Further sequencing of additional strains will allow a deeper 
understanding of the genomic source of virulence.  In several organisms, acquired 
segments of DNA are associated with the virulence of that strain (52).   For example, 
Escherichia coli 0157:H7 has 1300 genes that are not present in the Escherichia coli K12 
laboratory strain.  An antimicrobial agent that selectively inhibited the function of these 
genes would render the organism non-virulent but not kill it (53).  This could avoid the 
inflammatory response in the host that is caused when endotoxin from the gram-negative 
bacterial cell wall is released due to lysis of the bacterial cell (50).      
 The use of genomics has many advantages.  It may be used to find new and 
nontraditional protein targets which could be used as lead compounds for new drugs 
(42,52).  Drugs with limited spectrum of activity that are selective for a particular 
organism may be developed to avoid the destruction of normal bacterial flora in the host 
(52).  However, genomics does not consider cellular accumulation and efflux of the 
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compound being tested.  As a result, whole cell assays for testing each potential lead 
compound is required to consider these issues when looking for new drugs (47). 
 
 Combinatorial Chemistry 
 
 In the past two decades a new sub-specialty of chemistry, combinatorial 
chemistry, has emerged with a great potential to revolutionize the discovery of new 
medicinal agents and diagnostic reagents.  This special area of chemistry may increase 
the production of potential new drugs by using a set of innovative procedures to generate 
large libraries of compounds and identify the pharmacologically active ones (54).  The 
idea of combinatorial chemistry is to make a large number of chemical variants all at one 
time.  This may be accomplished by one of two methods:  solid-phase synthesis and 
solution-phase synthesis.  In solid-phase synthesis, the molecule of interest is attached to 
a polymeric carrier, such as a bead.  Chemical reactions that modify the molecule of 
interest occur on the bead until the desired library of compounds is formed.  Then the 
bead is separated from the compounds (See Figure 6).  One of the advantages of this 
method is the ability to drive reactions to completion by using excess of reagents (55).  
The excess reagents are then removed by filtration and washing. 
 
     + A linker   (a)          A    B   (b)        AB 
cleavage 
  (c) AB 
 
Figure 6.  Solid-phase synthesis.  (a)  The molecule of interest “A” is attached to a 
polymeric bead via a linker.  (b)  Substance B reacts with and binds to molecule A.  (c)  
The new molecule “AB” is cleaved from the bead (55). 
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 In liquid-phase synthesis, excess reagents cannot be removed by filtration because 
reagents are in solution.  However, scavenger molecules can remove excess reagents, 
allowing reactions to proceed to completion (See Figure 7) (55). 
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Figure 7.  Liquid-phase synthesis.  (a)  Molecule A is reacted with an excess of molecule 
B.  Both molecules are in solution.  This results in a combination of AB and B molecules 
in solution.  (b)  A scavenger molecule that is attached to a bead reacts with the excess B 
and is filtered off, leaving molecule AB (55). 
  
 By using these methods a plethora of compounds can be produced in a short 
period of time (56).  Biologically active compounds that are found (also known as “lead” 
agents) may be chemically modified in an attempt to find derivatives of the “lead” agents 
that have enhanced biological activity.  The “lead” agent may be chosen from a library of 
diverse agents by testing for a specific biological activity.  Combinatorial libraries of the 
“lead” agent may be made by one of two methods:  split synthesis or parallel synthesis 
(57).  In the split synthesis method, compounds are assembled on the surface of 
microparticles or beads.  The “lead” compound is attached to the beads.  Chemical 
components, or building blocks, are added to the “lead” compound.  In subsequent steps, 
beads from the previous step are mixed and partitioned into several groups and a new 
building block is added.  The process continues until the desired combinatorial library has 
been assembled.  Each bead holds a single library member and may be separated from the 
others by mechanical means (See Figure 8) (55).  In the parallel synthesis method, each 
compound is synthesized in a separate vessel.  The “lead” compound may be attached to 
scavenger 
scavenger 
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a microwell tray.  Each building block is added to the well and allowed to bind to the 
“lead” compound or previous building block.  Both the split synthesis and parallel 
synthesis lend themselves to automation.  Once a library of compounds is made, they can 
be tested for bioactivity by determining the ability to bind to a specific target or other 
desired properties.  The most promising compounds must be isolated and identified for 
further development (57).   
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Figure 8.  Split synthesis protocol (55). 
 
 There are several advantages to using combinatorial chemistry for discovery and 
development of new antimicrobial agents when compared to traditional methods.  A 
collection of natural products is not necessary for combinatorial chemistry because all 
compounds are synthetically made.  Combinatorial chemistry may be automated by 
robotic instrumentation that can make compounds and perform chemical and biological 
analysis with greater speed, accuracy, and precision than a laboratory scientist (58).  
Automation greatly decreases labor costs and allows huge numbers of compounds to be 
made and screened for biological activity in a short period of time. 
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Combinatorial chemistry may be used to produce compounds exhibiting both 
antibacterial and antifungal activity.  An agent that has biological activity against either 
bacteria or fungi can be modified by adding building blocks to produce activity against 
the other group of microorganisms.  Although little work has been done in this area, the 
methods used in combinatorial chemistry should allow production and screening of 
hundreds of agents that may have multiple antimicrobial indications. 
 
Bringing a Drug To Market 
 
Preclinical Trials 
 
 Once a compound has been identified as a potential new drug, it must go through 
a series of preclinical and clinical trials prior to being put on the market.  During 
preclinical trials, the compound must be tested in animal models to assess safety, 
distribution in various tissues, and efficacy against experimental bacterial infections.   
 Early stages of testing ensure that the compound is not rapidly metabolized in 
vivo and that it is well tolerated by the animals in which it is tested.  This is done by 
giving the drug by various routes of administration:  intravenously, subcutaneously, and 
orally.  The initial safety and metabolism is assessed for each form of administration.  
Typically 8-12 animals are used per administration route and dose.  The doses that are 
used in these trials are selected based upon anticipated levels that will be used during the 
clinical trials.  Blood samples are taken at strict time intervals after administration and 
analytical chemical methods, such as high-pressure liquid chromatography, are used to 
determine serum or plasma drug levels and to identify metabolites of the drug excreted in 
urine.  The serum/plasma levels allow the determination of elimination half-life, peak 
drug concentrations achieved, and Area Under the Curve (AUC), which is a measure of 
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how much of a drug reaches the bloodstream in a set period of time (59).  These 
parameters are determined for each species tested and can be used to predict how to use 
the drug in humans during the clinical trials.  These early trials also evaluate how well 
experimental infections are cured by the drug. 
 Once a potentially new antibiotic has been tested, the data is reviewed and a 
decision is made whether the perceived advantages of the compound warrant the time and 
expense required for clinical development.  Extensive safety evaluations must be done 
before proceeding (38). 
 
Animal Safety Studies 
 
 The purpose of animal safety studies is to assess the drug for short-term (acute) 
and long-term (chronic) dosing, genetic or carcinogenic safety, and affects on 
reproductive capability.  For acute studies, the drug is given over a 24 hour period at 
levels considerably above the anticipated level of use in humans.  The animals are 
monitored for behavioral changes along with lethality.  This allows the maximum 
tolerated dose to be determined.   
 Chronic studies use several different dosing schedules on multiple species of 
animals.  The drug is given for 30 days of duration at a level several fold above the 
expected human-use level.  Blood is drawn during these studies and tested for 
hematological and blood chemistry abnormalities, including liver and kidney function 
and central nervous system manifestations.  At the end of dosing, animals are sacrificed 
and multiple tissues are examined for gross and histological abnormalities.  If the drug is 
given perenterally, the injection site should be evaluated for irritation.  These studies 
must be done before the drug can go into Phase I clinical trials.  If the drug moves on to 
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Phase II clinical trials, a 6 month chronic study must be performed in at least 2 species of 
test animals.   
 Studies to assess reproductive capabilities are done to determine the effect on 
spermatogenesis in males and embryogenesis in females in animals receiving the drug.  
For mothers who received the drug during the gestational period, the effects of the drug 
on the fetus is evaluated by examination of the newborn for abnormalities.  For 
antimicrobial agents that give an abnormal response in these studies, a 2-year 
carcinogenicity study is performed in rodents.   
 Once all safety studies are completed, the data must be compiled and submitted to 
the Food and Drug Administration (FDA) before clinical trials can begin.  The FDA has 
30 days to review and approve the drug for further testing (38). 
 In addition to preclinical trials and safety studies, the manufacturing process for 
the new drug must be scaled up from the small quantity that has been required up to this 
point, while ensuring reproducibility of each lot with the original samples.  A 
determination must be made on the best way to produce large quantities of the drug to 
keep up with the demand for the new drug once approved.  Before clinical trials can 
begin, susceptibility testing products (Kirby Bauer disks, E-test strips, or microbroth MIC 
panels) must be developed (60). 
 
Clinical Trials 
 
 Clinical trials are divided into three phases and can take up to 5 years to complete.  
The FDA provides guidance on how these trials should be performed (61,62). 
 Phase I trials can take up to 2 years to complete and are performed to study the 
safety and pharmacokinetics profile in healthy volunteers.  They confirm achievable 
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blood levels, elimination half-life, urinary recovery in humans, and help determine the 
extent of oral absorption.  This data helps set up an appropriate dosing schedule for 
subsequent clinical trials. 
 Phase II trials can take up to 2 years to complete and are performed to assess the 
efficacy of the new antibiotic in treating patients with bacterial infections.  This phase is 
usually done using patients who do not have life-threatening infections.  The efficacy of 
the test drug is usually compared to a drug of known efficacy.  The efficacy of the drug is 
monitored by both clinical and bacteriological cure.  Clinical cure is determined by relief 
of symptoms and resolution of signs of infection.  Bacteriological cure is determined by 
eradication of the etiologic agent on culture.  During this phase, safety and toleration of 
the drug continue to be monitored (38). 
 Phase III trials can take several years and are similar to Phase II trials.  However, 
these trials are done to show efficacy of the drug for multiple therapeutic indications.  
The efficacy should be demonstrated for each organism at each site of infection at which 
an indication for therapy is desired.  The most meaningful data are obtained when the 
new drug is evaluated against a known standard therapy.  This allows evaluation of 
improved side effect profiles, reduced dosing frequencies, and reduced cost (38).   
 After clinical trials are completed, all the data must be organized and submitted to 
the FDA for approval.  The FDA takes about 21 months to review the data for approval.  
Once approved, the drug may be marketed and sold (38).   
 
Future of Antimicrobial Development 
 
 While there is a need to produce new antimicrobial agents, some pharmaceutical 
companies have decided to discontinue the development of this group of therapeutic 
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agents.  In the 1960’s, the FDA approved 2.9 new antibacterial drugs per year.  This 
decreased to 2.2 drugs per year in the 1990’s and 1.6 drugs per year between 2000 and 
2004.  There are many reasons for this decrease.  The profit for antimicrobial agents are a 
fraction of the profits for other types of drugs.  For example, a company’s best selling 
antibacterial agents made just over two billion dollars in 2003 compared to 9.3 billion 
dollars that was made on a lipid lowering agent sold by the same company.  The lower 
profit margin may be attributed to the short term use of the drug when compared to other 
types of medicine.  In addition, experts often recommend that newer antimicrobial agents 
be reserved for treating patients who have infections caused by resistant pathogens.  
Another contributing factor is the incredibly high cost of bringing a new antimicrobial to 
market.  It is estimated that it costs about 800 million dollars to discover, develop, 
perform trials, and bring a drug to market.  In the last several years, a number of large 
pharmaceutical companies have merged to form even larger companies.  Larger 
companies require larger profits to sustain themselves and may be less willing to develop 
drugs that have a lower profit margin.  Another deterrent to manufacturing antimicrobials 
is the length of time required to bring a drug to market and the regulatory requirements.  
The time from the discovery of a potential new drug to placing the drug on the market is 
up to ten years.  The FDA is very involved in the developmental process and reviews the 
data for the new drugs at several time intervals during development.  Even though the 
FDA is attempting to streamline this process, these changes cannot change a two billion 
dollar drug into a nine billion dollar drug (63). 
 Although the development of new antimicrobials has declined in recent decades, 
it is critical that research and development of antimicrobials continues.  Cost effective 
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screening methods, such as genomics and combinatorial chemistry may make discovery 
of new agents more efficient.  This coupled with a streamlined FDA process may reduce 
the cost and time required to bring a new drug to market.  These factors are of key 
importance if we are to continue a successful fight against infectious diseases. 
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MATERIALS AND METHODS 
 
Source of Compounds to be Tested 
 
 Combinatorial chemistry was used to produce sixty-one compounds in three 
general classes:  hydantoins, sulfonamides, and amides.  (See Table 1 for a list of 
compounds made.)  These compounds were made by a fellow graduate student, Alen 
Cusak, in the Chemistry Department.   
Table 1.  Name and number of chemical compounds used.   
Sample 
Number 
Chemical Name of Compound 
1 N-butyl-4-chlorobenzamide   
2 3,4-difluoro-N-(2-phenylethyl) benzenesulfonamide 
3 N-benzylbenzenesulfonamide 
4 N-(1-phenylethyl)benzenesulfonamide 
5 3,5-dibenzyl-1-(4-nitrobenzyl)hydantoin 
6 3,4-difluoro-N-(1-phenylethyl)benzenesulfonamide 
7 N-benzyl-3,4-difluorobenzenesulfonamide 
8 1,3,5-tribenzylhydantoin 
9 N-[3,5-bis(trifluoromethyl)benzyl]-4-fluorobenzenesulfonamide 
10 N-benzylbenzamide 
11 4-chloro-N-(2-phenylethyl)benzamide 
12 N-(1-phenylethyl)benzamide 
13 N-(2-phenylethyl)benzenesulfonamide 
14 3,5-dibenzyl-1-(4-methoxybenzyl)hydantoin 
15 3,5-dibenzyl-1-isopentylhydantoin 
16 N-butylbenzamide 
17 N-butylbenzenesulfamide 
18 4-chloro-N-(2-chlorobenzyl)benzamide 
19 N-benzyl-4-chlorobenzamide 
20 N-butyl-3,4-difluorobenzenesulfonamide 
21 4-chloro-N-octylbenzamide 
22 4-chloro-N-(1-phenylethyl)banzamide 
23 N-isobutyl-3,5-bis(trifluoromethyl)benzamide 
24 N-(2-chlorobenzyl)-4-fluorobenzenesulfonamide 
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25 3,5-dibenzyl-1-(3-nitrobenzyl)hydantoin 
26 N-(2-phenyletheyl)benzamide 
27 4-fluoro-N-(2-phenylethyl)benzenesulfonamide 
28 3,5-dibenzyl-1-hexylhydatoin 
29 N-(2-phenylethyl)-3,5-bis(trifluoromethyl)benzamide 
30 3,5-dibenzyl-1-heptylhydatoin 
31 3,5-dibenzyl-1-octylhydatoin 
32 3,4-difluoro-N-(2-phenylethyl)benzene 
33 4-chloro-N-(1-phenylethyl)benzene 
34 N-(2-chlorobenzyl)-3,4-difluorobenzenesulfonamide 
35 3,4-difluoro-N-octylbenzenesulfonamide 
36 N-benzyl-4-fluorobenzenesulfonamide 
37 3,5-dibenzyl-1-toluylhydatoin 
38 N-(2,4-dichlorobenzyl)-4-fluorobenzenesulfonamide 
39 3-benzyl-1-(2,4-difluorobenzyl)imidazolidine-2,4-dione 
40 3-(2-chlorobenzyl)-1-(3-chloro-4-methoxybenzyl)imidazolidine-2,4-dione 
41 3-benzyl-1-[4-(trifluoromethyl)benzyl]imidazolodine-2,4-dione 
42 4-chloro-N-(4-fluorobenzyl)benzamide 
43 3-benzyl-1-(4-fluorobenzyl)imidazolidine-2,4-dione 
44 3-(2-chlorobenzyl)-1-(5-fluoro-2-methoxybenzyl)imidazolidine-2,4-dione 
45 1,3-bis(2-chlorobenzyl)imidazolidine-2,4-dione 
46 3-benzyl-1-(3-methylbutyl)imidazolidine-2,4-dione 
47 3-(2-chlorobenzyl)-1-octylimidazolidine 
48 1-benzyl-3-(2-chlorobenzyl)imidazolidine-2-4-dione 
49 3-benzyl-1-(4-methoxybenzyl)imidazolodine-2,4-dione 
50 N-hexyl-3,5-bis(trifluoromethyl)benzamide 
51 1-[3,5-bis(trifluoromethyl)benzoyl]pyrrolidine 
52 N-(4-fluorobenzyl)-3,5-bis(trifluoromethyl)benzamide 
53 3,5-bis(trifluoromethyl)-N-[3-(trifluoromethyl)benzyl]benzamide 
54 4-fluoro-N-(4-fluorobenzyl)benzenesulfonamide 
55 1-[(4-fluorophenyl)sulfonyl]pyrrolidine 
56 4-fluoro-N-[3-(trifluoromethyl)benzyl]benzenesulfonamide 
57 N-(2-chlorobenzyl)-3,5-bis(trifluoromethyl)benzamide 
58 4-fluoro-N-hexylbenzenesulfonamide 
59 4-fluoro-N-isobutylbenzenesulfonamide 
60 N-benzyl-3,5-bis(trifluoromethly)benzamide 
61 N-[3,5-bis(trifluoromethyl)benzyl]-3,5-bis(trifluoromethyl)benzamide 
 
 The compounds were produced by attaching chemically reactive molecules to 
insoluble polymeric resin bead supports.  Reactions were driven to completion by using 
excess reagents.  After each step, purification of the resin-bound compounds was 
accomplished by filtrations and washing.  The desired product was then cleaved from the 
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resin bead.  (For a full description of how compounds were made, refer to Alen Cusak’s 
thesis [64].)   
 The hydantoins that were synthesized fell into two categories:  trisubstituted and 
disubstituted.    The trisubstituted hydantoins were made using the following formula: 
   
O
NH2
O 1. R1CHO
(CH3O)3CH
2. (CH3O)3CH
NaBH3CN
1% CH3COOH
O
NH
O
R1
R2NCO
CH2Cl2
O
N
O
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N
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O
CHCl3
Et3N
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N
O
O
R1
R2
Hydantoin
A B
C
D
 
 
 In this formula, a Wang resin bound amino acid (A) was reacted with various 
aldehydes (R1CHO) in the presence of trimethylorthoformate ((CH3O)3CH).  An imine 
intermediate was reacted with trimehylorthoformate and sodium cyanoborohydride 
(NaBH3CN) under acidic conditions provided by acetic acid (1% CH3COOH) and formed 
an N-alkylated resin (B).  The resin was washed to remove excess aldehydes and excess 
NaBH3CN and was then reacted with isocyanate (R2NCO).  The resultant compound (C) 
was filtered and washed to remove excess isocyanate.  A base induced cyclizative 
cleavage produced a relatively pure hydantoin (D) by causing the five member hydantoin 
ring to close and by cleaving the Wang resin from the hydantoin (64). 
 The disubstituted hydantoins were made using the following formula: 
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 The Wang resin (A) was reacted directly with isocyanate to generate a resin 
bound urea precursor (B).  It was washed with dichloromethane (DBM) to remove excess 
isocyanate.  The resin was cleaved using a strong base (DBU) yielding the disubstitued 
hydantoins (C) (64).   
 The amides and sulfonamides were made by a “catch and release” application 
using the following formulas: 
N
N
R1 Cl
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O
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 The polymer supported dimethylaminopyridines (PS-DMAP) resin (A) was 
placed in a reaction vessel and acid chlorides (B) or sulfonyl chlorides (G) were added.  
Upon reaction with acid chlorides (B) and sulfonyl chlorides (G) stable acyl-pyridinium 
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adducts (C) and sulfonyl-pyridinium adducts (H) were formed.  This reaction describes 
“the catch” step in “catch and release” application.  Acyl-pyridinium (C) and sulfonyl-
pyridinium (H) adducts were cleaved from the resin by nucleophilic attack of pyridinium 
adduct with primary amine (D and I).  The cleavage step is known as “release” (64). 
 The chemical properties of these polymers resulted in a product that had an oily 
consistency.  In order to test these chemical compounds for antimicrobial activity, a test 
system that would accommodate the oily consistency was developed.   
 
Bacterial and Fungal Isolates 
 
 The organisms used in this research were chosen to represent a wide range of 
bacteria and yeast.  Strains of bacteria chosen were susceptible to most antibiotics that are 
tested in a clinical laboratory.  The gram-positive organisms included Staphylococcus 
aureus (ATCC strain 25923) and a clinical isolate of Group B streptococci (or 
Streptococcus agalactiae).  The gram-negative organisms included Escherichia coli 
(ATCC strain 35922) and Klebsiella oxytoca (ATCC strain 49131).   
 The yeasts used in this research were strains isolated from clinical specimens.  
The species chosen are generally susceptible to the most commonly used antifungal 
agents.  The yeasts used were Candida albicans, Candida tropicalis, and Candida 
parapsilosis.   
 
Inoculation of Media   
 
 In each of the experiments in this research, the media were inoculated by making 
a standardized suspension of the organism to be tested in sterile saline (0.85%) or 
Trypticase Soy Broth (TSB).  This suspension was made by touching a swab to 2-3 
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colonies of the test organism grown on Trypticase Soy Agar (TSA) with 5% sheep blood.  
The swab was then plunged into a tube of sterile saline and twirled until a homogeneous 
suspension was made.  A clean sterile swab was placed in the tube of the standardized 
inoculum.  As the swab was removed from the tube, it was pressed against the side of the 
tube to express the excess liquid.  Next, the swab was rubbed over the entire surface of 
the agar in one direction.  The plate was then turned and the swab was rubbed over the 
entire surface in two additional directions.  This technique ensured homogeneous growth 
of the organism on the plate (See Figure 9). 
 
 
Figure 9.  Diagrammatic representation of plate inoculation. 
 
Inoculum Size 
 
 The available literature (68,87) is very specific about the proper inoculum size 
that should be used when performing susceptibility testing on bacteria.  A suspension 
equaling a 0.5 McFarland [which is equivalent to approximately 1-2 X 108 Colony 
Forming Units/ml (CFU/ml)] was used in this research.  The inoculum size was 
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confirmed by placing the inoculum tube in a turbidity meter (Figure 10) and adjusted to a 
specific turbidity range specified by the meter manufacturer.   
 
 
Figure 10.  Turbidity meter. 
 
 There are various published inoculum sizes that may be used for yeast.  Some 
studies suggest the use of a 0.5 McFarland suspension while others suggest various 
dilutions of this 0.5 McFarland suspension (65,66,67).  In order to determine the best 
inoculum size for this research, a 0.5 McFarland suspension was made (using a turbidity 
meter) in trypticase soy broth (TSB) for each yeast to be tested.  These suspensions were 
then serially diluted in TSB to 1:100 and 1:2000.  RPMI 1640 media (to be described 
later) was inoculated as described above.  After the plates were incubated for 20-24 hours 
at 36oC, the plates from the 0.5 McFarland suspension were the only plates to show 
confluent growth.  As a result, it was determined that this was the best inoculum size.  
Since yeast grow more slowly than bacteria, the plates containing yeast were then 
reincubated and examined again after 36-48 hours to see if the results would be different 
after 48 hours of incubation.  The 0.5 McFarland suspension was still the best inoculum 
size.  As a result, a 0.5 McFarland suspension of yeast was used for the remainder of this 
research.  This is equivalent to approximately 1-5 X 106 cells per mL. 
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Incubation Time   
 
 The incubation time required for adequate growth of bacteria to detect inhibition 
by antimicrobial compounds is well defined (68).  An incubation time of 16-24 hours at 
36oC is recommended.  As with the inoculum size, the incubation time for yeast was not 
as well defined.  During the experiment where the optimal inoculum size was determined, 
the plates were observed for growth at both 20-24 hours and 36-48 hours to determine the 
optimal incubation time.  Adequate growth to allow detection of growth inhibition was 
seen at 20-24 hours.  This incubation time was used for the remainder of the study. 
 
Dimethyl Sulfoxide (DMSO) for Putting Compounds into Solution 
 
 The compounds that were tested were received in the microbiology laboratory as 
oily residues that were attached to the surface of glass vials.  In order to test these 
compounds, they had to be suspended in solution.  According the NCCLS guidelines for 
antibacterial susceptibility testing, many antimicrobial substances are soluble in water 
(69).  However, a number of antimicrobial substances are not soluble in water and 
another diluent must be used.  Some of the diluents suggested are phosphate buffer, 
sodium bicarbonate, dimethyl sulfoxide (DMSO), saline, acetic acid, ethanol, sodium 
hydroxide, methanol, and hydrochloric acid.  In addition, the NCCLS guidelines for 
Antifungal Susceptibility Testing of Yeast (70) recommends the use of dimethyl 
sulfoxide (DMSO) to dissolve antifungal agents that are not water soluble.  Since it was 
not known if the sixty-one substances that were tested were soluble in water, an “all-
purpose” diluent was needed to suspend them in solution.  Since many antibacterial 
agents are soluble in DMSO, it was used as the “all-purpose” diluent.  
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 When using DMSO to dissolve antifungal powders as directed in the NCCLS 
guidelines, the DMSO is greatly diluted prior to inoculating organisms into the various 
concentrations of the antifungal agent.  If the NCCLS guidelines are followed, the final 
concentration of DMSO would be only 1% of its original concentration.  In addition, the 
antifungal agent would be diluted to 1% of its original concentration.  Since the potency 
and purity of the compounds being tested were not known, there was a concern that high 
dilutions of the compounds may interfere with the ability to detect antimicrobial activity.  
Therefore, the smallest dilution possible of the compound should be used for testing.  
However, it was also necessary to ensure that the concentration of the DMSO used would 
not interfere with testing of the compounds. 
 To determine lowest concentration of DMSO that may be used to dissolve the 
compounds without inhibiting the test organisms, a 0.5 McFarland suspension of each 
test organism was made in 0.85% saline.  Each organism was inoculated to either RPMI 
1640 agar, Mueller Hinton agar, or Mueller Hinton agar with Sheep Blood.  (Discussed 
later.)   
 Dilutions of the DMSO were made in sterile water.  (1:1 [undiluted], 1:5, 1:10, 
1:15, 1:20 dilutions were made.)  Sterile filter paper disks were then dipped into the 
dilutions of the DMSO and placed on the surface of the Mueller Hinton, Mueller Hinton 
with Blood, and RMPI media.  Each organism was tested with each dilution of DMSO. 
 The plates were incubated for 20-24 hours at 36oC and then examined for 
inhibition of growth around the disk.  Table 2 shows the results of this experiment. 
 
 
 
 
 
40  
 Table 2.  Zones of inhibition for DMSO dilutions. 
  DMSO Dilutions (Zone sizes in mm)* 
 1:1 1:5 1:10 1:15 1:20 
E. coli 0 0 0 0 0 
S. aureus 0 0 0 0 0 
K. oxytoca 0 0 0 0 0 
Group B Strep 0 0 0 0 0 
C. albicans 0 0 0 0 0 
C. tropicalis 7 0 0 0 0 
C. parapsilosis 0 0 0 0 0 
* Note:  The disk size was 6 mm in diameter.  If no zone was noted, the result was 
recorded as "0 
 
 Only one organism was inhibited by undiluted (1:1) DMSO.  None were inhibited 
by a 1:5 dilution of DMSO.  As a result, a 1:5 dilution was used for further testing. 
 
Volume of Liquid to Place on Filter Paper Disks 
 
 When testing the dilutions of DMSO, the filter paper disks were dipped into the 
various dilutions and placed onto the media.  It was noted that the disks were very wet 
and did not stick well to the surface of the agar.  This caused slight movement of the 
disks on the media and allowed accumulation of the DMSO in small puddles.  This 
resulted in the liquid running over the surface of the plate away from the disks.  Instead 
of dipping the disks in the solutions, it was hypothesized that placing a measured volume 
onto the disks would allow the disk to be saturated without being too wet.  To determine 
this measured volume, filter paper disks were placed on an absorbent paper towel.   
Various volumes of a dark liquid (crystal violet stain) were pipeted onto the disks using 
an MLA pipet with disposable tips to determine the volume of liquid that was absorbed 
by the disks.  After the crystal violet was pipeted, the disk was moved off of the paper 
towel to see if the disk was able to absorb the volume without excessive absorption by the 
paper towel.  Table 3 shows the results of this experiment. 
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Table 3.  Crystal violet volume required to saturate disk. 
Crystal Violet Volume Disk Description Paper Towel Description 
10 ul Absorbed all crystal violet No absorption of crystal 
violet 
20 ul Absorbed all crystal violet Minimal absorption of 
crystal violet 
30 ul Over-saturated by crystal 
violet 
Excessive absorption of 
crystal violet 
 
 Since the disks absorbed 20 μl of crystal violet with minimal absorption on the 
paper towel, this is the volume that was pipeted onto the disks in future experiments.  
 
Evaluation of Testing Interference Due to Resin Beads 
 
 Resin beads were used in the production of each of the compounds to be tested.  
Although most beads were removed from the compounds during the final step of the 
combinatorial chemistry, a few beads remained in the samples.  It was unknown whether 
these beads would interfere with the experiments of determining antibacterial or 
antifungal activity of the compounds.  In order to determine if the resins would interfere, 
a 0.5 McFarland suspension was made of each organism and inoculated to appropriate 
plates.  The resin was suspended by adding 100 μl of DMSO and 400 μl of water to a 
bottle that was coated with the resin beads.  (It was the original bottle in which the resin 
beads were received and was left over from the combinatorial chemistry experiments 
performed by Alen Cusak.)  Twenty microliters (μl) of this resin suspension was pipetted 
onto each of 7 filter paper disks.  One disk was placed on each plate and inoculated for 
20-24 hours.  After this incubation, the plates were examined for zones of inhibition.  
Table 4 shows the results of this experiment. 
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Table 4.  Zones of inhibition for resin beads. 
 Zone size in mm* 
E. coli 0 
S. aureus 0 
K. oxytoca 0 
Group B Strep 0 
C. albicans 0 
C. tropicalis 0 
C. parapsilosis 0 
* Note:  The disk size was 6 mm in diameter.  If no zone was noted, the result was 
recorded as "0". 
 
 Since no inhibition was noted, the resin beads do not appear to affect the growth 
on the test organisms and was acceptable to use in this research. 
 
Evaluation of the Newly Developed Test System 
 
 Once all of the variables in the test system were evaluated, it was necessary to test 
the entire system to confirm that antibacterial and antifungal activity could be detected.  
To do this a 0.5 McFarland suspension was made for each organism and inoculated to the 
appropriate media.  Escherichia coli, Staphylococcus aureus, and Klebsiella oxytoca 
were plated to Mueller Hinton agar.  Group B Strepotococcus was inoculated to Mueller 
Hinton agar with sheep blood.  Candida albicans, Candida tropicalis, and Candida 
parapsilosis were inoculated to RPMI medium.  Antimicrobial powders for known 
antibacterial and antifungal agents (ciprofloxacin, amphotericin, and fluconazole) were 
put into solution for testing.  This was done by placing a small amount of each powder 
(approximately 0.01 grams) into a vial and adding 100 μl of DMSO and 400 μl of water.  
The vial was gently swirled until the powder went into solution.  Twenty μl of each 
solution was pipetted onto each of 7 filter paper disks.  One disk for each antimicrobial 
agent was placed on each plate and incubated for 20-24 hours at 36oC.  After this 
incubation, the plates were examined for zones of inhibition.  See Table 5 for results. 
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Table 5.  Zones of inhibition for antimicrobial control compounds. 
 Antimicrobial Solutions (Zone sizes in mm)* 
 Ciprofloxacin Amphotericin-B Fluconazole 
E. coli 39 0 0 
S. aureus 36 0 0 
K. oxytoca 35 0 0 
Group B Strep 31 0 0 
C. albicans 0 18 0 
C. tropicalis 0 18 0 
C. parapsilosis 0 20 33 
* Note:  The disk size was 6 mm in diameter.  If no zone was noted, the result was 
recorded as "0". 
 
 The test system worked well for detection of anti-bacterial activity and was 
acceptable for further testing.  However, the zone sizes for the fungi were much smaller 
than the zone sizes for the bacteria and fluconazole demonstrated no activity against two 
of the fungi (C. albicans and C. tropicalis).  Because of these results, there was a concern 
that the media formulation may not be optimal.  Further investigation was done to see if 
the media formulation could be improved.   
 
Media 
 
 The media used when screening for antimicrobial activity can have a dramatic 
effect on the results of an experiment.  These media must fulfill two requirements:  1) 
support the growth of the organism being tested and, 2) allow inhibition of growth to be 
detected due to the presence of the compound being tested.    Although this research was 
not done to perform susceptibility testing on clinical isolates of bacteria, Mueller Hinton 
agar and Mueller Hinton agar with sheep blood , the media used in clinical laboratories 
for bacterial susceptibilities as outlined in the NCCLS M2-A7 document (68), were 
suitable and effective for this research.     
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 The medium used for the fungal isolates was less well defined.  A number of 
different media have been described for testing fungal isolates.  These include glucose-
enriched Mueller Hinton agar (71), high resolution medium, high resolution medium with 
methylene blue (72), and RPMI medium.  The NCCLS document M27-A describes 
media that may be used for fungal susceptibility testing and states that RPMI 1640 
medium is “at least as satisfactory as several other synthetic media” (70).  RPMI medium 
was chosen as the medium for this research.  To make this medium 10.5 grams of RMPI 
1640 powder was added to one liter of deionized water.  In addition, 20 grams of Bacto 
agar was added to cause the medium to gel.  The medium was then autoclaved at 121oC 
for 20 minutes.  After autoclaving, the medium was cooled to about 60oC and poured into 
empty, sterile petri dishes.  The dishes were left at room temperature for about 30 
minutes to allow them to cool and gel.  Once gelled, the plates were stored at 4oC until 
used. 
 From the results of the quality control experiment that was performed to evaluate 
the test system that was developed, there was a concern that the fungal medium 
formulation may not be optimal.  A new formulation of the RPMI 1640 medium and 
another readily available medium, Sabarouds Dextrose Agar (SDA), were considered for 
use in this study.  The new formulation of the RPMI 1640 medium included MOPS 
buffer [3-(N-morpholino) propanesulfonic acid] to adjust the pH to 6.9-7.1.  To make this 
medium 10.5 grams of RMPI powder, 20 grams of Bacto agar, and 34.53 grams of 
MOPS buffer powder were added to 900 ml of deionized water.  The pH was adjusted by 
adding a 1 molar sodium hydroxide solution until the pH was between 6.9 and 7.1.  The 
pH was determined by placing strips of pH paper in the liquid medium and then 
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comparing the color to a pH chart.  After the proper pH was achieved, water was added to 
bring the volume to 1 liter.  The medium was then autoclaved at 121oC for 20 minutes.  
After autoclaving, the medium was cooled to about 60oC and poured into empty, sterile 
petri dishes.  The dishes were left at room temperature for about 30 minutes to allow 
them to cool and gel.  Once gelled, the plates were stored at 4oC until used. 
 To test the new formulation of RPMI 1640 medium and SDA, a 0.5 McFarland 
suspension was made for each of the yeast and inoculated to both the old and new 
formulations of RMPI media and the SDA.  Antimicrobial powders for amphotericin, and 
fluconazole were put into solution (as described earlier) and placed on a filter paper disk 
for testing as described above.  A 20 μl MLA pipettes was used to transfer the fluid onto 
the disks.  One disk for each antimicrobial agent was placed on each plate and inoculated 
for 20-24 hours at 36oC.  After this incubation, the plates were examined for zones of 
inhibition.  (See Table 6 for results.) 
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Table 6.  Zones of inhibition for media formulations. 
 RMPI – Original Formulation (Zone sizes in mm)* 
 Amphotericin-B Fluconazole DMSO Resin 
C. albicans 16 0 8 0 
C. tropicalis 17 0 0 0 
C. parapsilosis 20 42 0 0 
 
 RMPI – With MOPS Buffer (Zone sizes in mm)* 
 Amphotericin-B Fluconazole DMSO Resin 
C. albicans 18 0 0 0 
C. tropicalis 18 0 0 0 
C. parapsilosis 22 42 0 0 
 
 SDA (Zone sizes in mm)* 
 Amphotericin-B Fluconazole DMSO Resin 
C. albicans 13 0 0 0 
C. tropicalis 10 0 0 0 
C. parapsilosis 12 32 0 0 
* Note:  The disk size was 6 mm in diameter.  If no zone was noted, the result was 
recorded as "0". 
 
 At the completion of this testing, it was determined that the RPMI 1640 with 
MOPS buffer was the best medium for detecting antifungal activity because it 
demonstrated the largest zone sizes but was not affected by DMSO.  As a result, it was 
used for the remainder of fungal testing in this research. 
 
Testing Compounds 
 
 Once the testing system was validated using known antimicrobial agents, it was 
possible to start testing the compounds provided by Alen Cusak, my colleague in the 
chemistry department.  To do this, a 0.5 McFarland suspension was made for each of 
seven organisms and inoculated to the appropriate testing media.  Chemical compounds 
produced by Alen were put into solution for testing by adding 100 μl of DMSO and 400 
μl of water to the vial in which the compound was received.  The vial was gently swirled 
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until the compound went into solution.  Twenty μl of each solution was pipetted onto 
each of 7 filter paper disks.  One disk for each compound was placed on each plate and 
inoculated for 20-24 hours at 36oC.  After this incubation, the plates were examined for 
zones of inhibition.  Results for each compound are found in the Table 11 in the 
“Results” section.  Figures 11a and 11b demonstrate the zones of inhibition that were 
noted.  The diameter of the zones were measured.  The zone of inhibition was defined as 
the area where colonies failed to grow. 
 
Figure 11a:  RPMI 1640 Agar Figure 11b:  Mueller Hinton Agar 
 
Figure 11a and 11b.  Photographs of RPMI 1640 and Mueller Hinton agars demonstrating 
zones of inhibition. 
 
 
Effect of DMSO and Resin Beads on a Cell Culture System 
 
 Two compounds were found to have both antibacterial and antifungal activity.  As 
mentioned earlier, all potential new antimicrobial agents must be tested for toxicity 
before clinical trials can begin.  One way to perform cytotoxicity testing is to inoculate 
the compounds to live cells and observe for cytotoxic effects.  Before that could be done, 
a test system had to be developed to ensure that results that would be obtained would be 
due to the compound being tested and not some other variable in the experiment. 
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 The two compounds that were mentioned above were made on resin beads and 
DMSO was used to put the substances into solution.  It was necessary to ensure that the 
resin beads and DMSO did not interfere with the cell culture test system.  To do this, a 
bottle that was coated with resin beads was rinsed with 2 mL of sterile saline to suspend 
the resin beads in liquid.  One mL of the resin bead solution was mixed with 1 mL of cell 
culture maintenance medium.  (This medium contains proteins, buffer to control pH, and 
antibiotics to inhibit growth of bacteria and fungi (73) and is used to maintain the 
viability of the cells in a cell culture.)  In addition, a 1:5 dilution of DMSO was made in 
the maintenance medium (200 μl of DMSO added to 800 μl of the maintenance medium).    
 The above solutions were inoculated into three living cell lines (human:  MRC-5, 
A549;  monkey:  RMK).  To do this, the maintenance medium that is routinely found in 
the cell culture tubes when purchased was discarded by inverting the tube and allowing 
the medium to run out into a waste container.  Then 1.0 mL of the resin or DMSO 
solutions was inoculated to each tube.  The tubes were placed into a rotating drum 
(Figure 12) and incubated up to 7 days at 36oC.  In the rotating drum, the tubes were lain 
on their sides and the medium periodically washed over the cell monolayer as the drum 
rotated and exposed the cells to the resin beads or DMSO.  The tubes were observed for 
cytotoxicity at 24 hours, 48 hours, and 7 days.  If cytotoxicity was observed in any tube, 
incubation was discontinued for that tube.  Table 7 shows the results for this experiment. 
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Figure 12.  Rotating drum for cell culture tubes. 
 
Table 7.  Cytotoxicity of DMSO and resin beads. 
 MRC-5 A549 RMK 
DMSO Toxicity at 24 hours Toxicity at 24 hours Toxicity at 24 hours 
Resin No toxicity after 7 days No toxicity after 7 days No toxicity after 7 days 
 
 The resin beads did not effect the cell lines.  However, the 1:5 dilution of DMSO 
that was used to put all compounds into solution caused cytotoxicity in all cell lines.  As a 
result, this dilution of DMSO could not be used for testing in the cell lines and additional 
testing was required to find another diluent that may be used that would not cause 
cytotoxcity. 
 
Determination of Best Diluent for Cytotoxicity Experiments 
 
 Since DMSO at a 1:5 dilution was not an acceptable diluent to use to put 
compounds into solution to test for toxicity in live cell lines, an alternate diluent had to be 
found to dilute compounds.  NCCLS guidelines (68,70) indicate that some antimicrobial 
substances may be diluted with ethanol or water.  To test the ethanol, 95% ethanol was 
diluted with cell culture maintenance media to make dilutions of 1:5, 1:10, and 1:20.  
Each of these dilutions, in addition to the neat 95% ethanol, was inoculated to the three 
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living human and monkey cell lines by discarding the cell culture maintenance medium 
that was in each tube and adding 1.0 mL of an ethanol solution to each tube.  The tubes 
were placed into a rotating drum and incubated up to 7 days at 36oC.  The tubes were 
observed for cytotoxicity at 24 hours, 48 hours, and 7 days.  If cytotoxicity was observed 
in any tube, incubation was discontinued for that tube.  Table 8 shows the results of this 
experiment. 
Table 8.  Cytotoxicity of DMSO dilutions and ethanol. 
 MRC-5 A549 RMK 
95% 
Ethanol 
Little or no CPE, 
Questionaable viability 
of cells 
Little or no CPE, 
Questionaable viability 
of cells 
Little or no CPE, 
Questionaable viability 
of cells 
1:5 
Dilution 
Toxicity at 24 hours Toxicity at 24 hours Toxicity at 24 hours 
1:10 
Dilution 
Toxicity at 24 hours Toxicity at 24 hours Toxicity at 24 hours 
1:20 
Dilution 
Toxicity at 24 hours Toxicity at 24 hours Toxicity at 24 hours 
 
 All tubes showed cytotoxicity except the 95% ethanol tubes.  However, the cells 
in the tubes with 95% ethanol looked unusual.   Since all other tubes showed toxicity, 
there was concern that cytoxicity was not demonstrated in the 95% because the cells were 
fixed or “pickled”.  Since most tubes demonstrated cytotoxicity, ethanol is not an 
acceptable diluent for putting compounds into solution.  Further testing was required to 
find other possible diluents. 
 To determine if water was a suitable diluent for the two compounds, a small 
portion of the oily powder for each compound was placed in a test tube.  A few drops of 
water were added to each tube.  The tubes were then observed to see if the compounds 
would dissolve.  Table 9 shows the results of this experiment and indicates that neither 
compound was soluble in water. 
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Table 9.  Water as a possible diluent for two compounds. 
Compound 21      Powdered crystals observed after 
water added.   
Compound 35     Powdered crystals observed after 
water added 
 
 Since neither the ethanol nor water were acceptable diluents, another alternative 
had to be considered.   A steroid diluent was considered as an option.  However, since 
this diluent was not a known antimicrobial diluent, there was concern that this would 
introduce a potentially unnecessary variable into this research.   
 Although it was demonstrated that a 1:5 dilution of DMSO was an unacceptable 
diluent, higher dilutions of DMSO might work as a suitable diluent.  To test this, DMSO 
was diluted 1:10, 1:20, 1:40, and 1:80 using cell culture maintenance medium.  Each of 
these dilutions was inoculated into the three living human and monkey cell lines.  To do 
this, the maintenance medium that was in each tube was discarded.  Then 1.0 mL of each 
DMSO dilution was inoculated into each tube.  The tubes were placed into a rotating 
drum and incubated up to 7 days at 36oC.  The tubes were observed for cytotoxicity at 24 
hours, 48 hours, and 7 days.  If cytotoxicity was observed in any tube, incubation was 
discontinued for that tube.  See Table 10 for results. 
 
Table 10.  Toxicity of DMSO at high dilutions. 
DMSO MRC-5 A549 RMK 
1:10 
Dilution 
Toxicity at 24 hours Toxicity at 24 hours Toxicity at 24 hours 
1:20 
Dilution 
Toxicity at 24 hours Toxicity at 48 hours Dropped tube, Unable 
to assess toxicity  
1:40 
Dilution 
No toxicity noted at 7 
days 
No toxicity noted at 7 
days 
No toxicity noted at 7 
days 
1:80 
Dilution 
No toxicity noted at 7 
days 
No toxicity noted at 7 
days 
No toxicity noted at 7 
days 
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 All cell lines demonstrated cytotoxicity in the 1:10 dilution of DMSO.  At the 
1:20 dilution, two of the cell lines demonstrated cytotoxicity.  (It was not possible to 
examine the RMK cells at the 1:20 dilution because the tube was dropped.)  At the 1:40 
dilution, no cytotoxicity was noted in any cell line.  As a result of this experiment, it was 
determined that a 1:40 dilution of the DMSO could be used to dissolve each compound 
for toxicity studies. 
 
Testing Compounds for Toxicity 
 
 Each compound that had both antibacterial and antifungal activity was tested to 
determine if they produced cytotoxicity in human and monkey cell lines.  To do this,  
80 μl of DMSO was pipetted into the vials of the two compounds to be tested in order to 
put the powder into solution.  1.120 mL of water was added to each tube.  Two mL of cell 
culture maintenance medium was used to bring each diluted sample to a 1:40 dilution of 
DMSO.  The 1:40 dilution was inoculated to the three living human and monkey cell 
lines.  To do this, the cell culture maintenance medium that was in each tube was 
discarded.  Then 1.0 mL of each compound diluted in DMSO and maintenance medium 
was inoculated to each tube.  The tubes were placed into a rotating drum and incubated 
up to 7 days at 36oC.  The tubes were observed for cytotoxicity at 24 hours and 7 days.  If 
cytotoxicity was observed in any tube, incubation was discontinued for that tube.  Results 
may be found in Table 15 in the “Results and Discussion” section. 
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RESULTS  
 
Activity of Chemical Compounds 
 
 The test system that was developed to look for antibacterial and antifungal 
activity worked well on the sixty-one compounds that were tested.  Table 11 shows the 
zones of inhibition for each compound that was tested against the seven test organisms. 
Table 11.  Zones of inhibition for each compound. 
 Zone Sizes in mm* 
Compound  C.tropicalis C  albicans C.parapsilosis Group B 
Streptococcus 
S. aureus K. oxytoca E. coli 
1 0 0 0 0 0 0 0 
2 0 0 0 0 0 0 0 
3 0 0 0 0 7 0 0 
4 0 0 0 0 0 0 0 
5 0 0 0 0 0 0 0 
6 0 0 0 0 0 0 0 
7 0 0 0 0 0 0 0 
8 0 0 0 0 0 0 0 
9 0 0 0 0 0 0 0 
10 0 0 0 0 9 0 0 
11 0 0 0 0 7 0 0 
12 0 0 0 0 0 0 0 
13 0 0 0 0 8 0 0 
14 0 0 0 0 0 0 0 
15 0 0 0 0 0 0 0 
16 0 0 0 0 0 0 0 
17 0 0 0 0 0 0 0 
18 0 0 0 0 0 0 0 
19 0 0 0 0 0 0 0 
20 0 0 0 0 0 0 0 
21 16 15 14 11 11 15 14 
22 0 0 0 0 0 0 0 
23 0 0 0 0 0 0 0 
24 0 0 0 0 0 0 0 
25 0 0 0 0 0 0 0 
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26 0 0 0 0 12 0 0 
27 0 0 0 0 0 0 0 
28 0 0 0 0 0 0 0 
29 0 0 0 0 0 0 0 
30 0 0 0 0 0 0 0 
31 0 0 0 0 0 0 0 
32 0 0 0 0 0 0 0 
33 0 0 0 0 0 0 0 
34 0 0 0 0 0 0 0 
35 18 10 10 11 11 11 13 
36 0 0 0 0 0 0 0 
37 0 0 0 0 0 0 0 
38 0 0 0 0 0 0 0 
39 0 0 0 0 0 0 0 
40 0 0 0 0 0 0 0 
41 0 0 0 0 0 0 0 
42 0 0 0 0 0 0 0 
43 0 0 0 0 0 0 0 
44 0 0 0 0 0 0 0 
45 0 0 0 0 0 0 0 
46 0 0 0 0 0 0 0 
47 0 0 0 0 0 0 0 
48 0 0 0 0 0 0 0 
49 0 0 0 0 0 0 0 
50 0 0 0 0 0 0 0 
51 0 0 0 0 0 0 0 
52 0 0 0 0 0 0 0 
53 0 0 0 0 0 0 0 
54 0 0 0 0 0 0 0 
55 0 0 0 0 0 0 0 
56 0 0 0 0 0 0 0 
57 0 0 0 0 0 0 0 
58 0 0 0 0 0 0 0 
59 0 0 0 0 0 0 0 
60 0 0 0 0 0 0 0 
61 0 0 0 0 0 0 0 
* Note:  The disk size was 6 mm in diameter.  If no zone was noted, the result was 
recorded as "0". 
 
 Seven compounds exhibited biological activity.  Two of these compounds (21 and 
35) had activity against all organisms tested.  Five compounds (3, 10, 11, 13, and 26) had 
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activity against just Staphylococcus aureus.  The names of these compounds and their 
chemical structures are found in Table 12. 
 
Table 12.  Names and chemical structures of biologically active compounds. 
Compounds With Both Antibacterial and Antifungal Activity 
Number Chemical Name Chemical Structure 
21 4-chloro-N-octylbenzamide 
35 3,4-difluoro-N-octylbenzenesulfonamide 
Compounds With Only Antibacterial Activity 
3 N-benzylbenzenesulfonamide 
10 N-benzylbenzamide 
11 4-chloro-N-(2-phenylethyl)benzamide 
13 N-(2-phenylethyl)benzenesulfonamide 
26 N-(2-phenyletheyl)benzamide 
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 After using combinatorial chemistry to produce the chemical compounds, analysis 
of the compounds indicated that impurities were present.  Both compounds 21 and 35 
contained octylamine as an impurity (64). Additional testing was done to determine if 
octylamine could inhibit the growth of the bacteria and fungi in this study.  Initial testing 
was performed using undiluted octylamine (99.9% pure).  All organisms that 
demonstrated inhibition with the undiluted octylamine were tested using 1:5, 1:10, and 
1:100 dilutions of the octylamine.  Table 13 shows the results of this testing.      
 
Table 13.  Zones of inhibition caused by dilutions of octylamine. 
 Octylamine Dilution (Zone Diameter*) 
Organism Undiluted 1:5 1:10 1:100 
E. coli 10 0 0 0 
K. oxytoca 10 0 0 0 
S. aureus 10 0 0 0 
Group B Streptococcus 0 - - - 
C. albicans 0 - - - 
C. tropicalis 0 - - - 
C. parapsilosis 0 - - - 
* Note:  The disk size was 6 mm in diameter.  If no zone was noted, the result was 
recorded as "0". 
 
 Although three of the organisms tested were inhibited by 99.9% pure octylamine, 
a 1:5 dilution (representing a concentration of 20%) resulted in the lack of inhibition.  
Although the purity of compounds 21 and 35 was not indicated in Alen Cusak’s thesis, all 
other amides and sulfonamides tested had purities of 59-99%.  It is very unlikely that the 
octylamine impurity reached a concentration of 20% in the tested compounds.  As a 
result, it is unlikely that the small amount of octylamine in the samples affected the 
results of this study.   
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Replicate Testing 
 
 To ensure that the results for this study could be replicated, the testing was 
repeated for all agents that exhibited antimicrobial activity.  The two agents that 
demonstrated both antibacterial and antifungal activity were tested in duplicate.  Due to 
limitations in the remaining amount of the compounds and supplies, the agents that 
demonstrated only bacterial activity were repeated in singlet.  The results of the original 
testing and the repeat testing are shown in Table 14.  (Note:  Compound 3 was not 
retested due to insufficient quantity of the compound.) 
 
Table 14.  Replicate testing of biologically active compounds. 
 Zone Sizes in mm* 
Compound 
** 
C.tropicalis C albicans C.parapsilosis Group B 
Streptococcus 
S. aureus K. oxytoca E. coli 
21 – O 16 15 14 11 11 15 14 
21 – R 23 20 20 12 12 12 13 
21 – R 22 20 18 12 12 12 13 
35 – O 18 10 10 11 11 11 13 
35 – R 23 21 18 13 11 12 13 
35 – R 23 21 18 13 11 12 13 
10 – O 0 0 0 0 9 0 0 
10 – R 0 0 0 0 8 0 0 
11 – O 0 0 0 0 7 0 0 
11 – R 0 0 0 0 7 0 0 
13 – O 0 0 0 0 8 0 0 
13 – R 0 0 0 0 8 0 0 
26 – O 0 0 0 0 12 0 0 
26 – R 0 8 0 0 11 0 0 
* Note:  The disk size was 6 mm in diameter.  If no zone was noted, the result was 
recorded as "0". 
** O = Original Test R = Repeats 
 
 The repeat testing confirmed that each compound exhibited antimicrobial activity.  
It should be noted that the zones of inhibition for the bacteria when repeated were within 
1 mm of the original results.  There was only one exception to this finding.  Klebsiella 
oxytoca when tested against compound 21 was originally 15 mm but was 12 mm upon 
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repeat testing.  A less dense inoculum on the original test could have caused this variance 
from the original results for this organism.  Klebsiella oxytoca produces a large capsule 
when it is grown on culture media.  This causes the colonies to be mucoid and sticky and 
can make it difficult to separate the individual bacterial cells and obtain a homogeneous 
inoculum.  If a larger inoculum size was used in the repeat experiment due to sticky 
clusters of the organism in the TSB, the zone sizes would have been smaller than the 
original test.  
 The yeast had a wider variation in the zones of inhibition than the bacteria on the 
repeats when compared to the original test.  The most probable explanation for this 
difference is the thickness of the RPMI media that was used.  It is known that when 
performing Kirby Bauer susceptibility testing, the thickness of the media can have an 
effect on the zone of inhibition.  When the filter paper disk impregnated with a particular 
antimicrobial agent is placed on the media used for testing, the antimicrobial agent begins 
to diffuse out of the filter paper disk and into the agar in all directions away from the 
disk.  In thin agar plates, the compound will reach the bottom of the media quickly and 
will start to diffuse laterally away form the disk, producing a high concentration of the 
agent relatively far away from the disk.  In thicker agar, it takes longer for the agent to 
reach the bottom of the agar and causes a higher concentration of the agent near the disk 
(See Figure 13) (87).  The difference in the concentration of the antimicrobial agent 
around the disk will result in a difference in the diameter of the zone of inhibition.   
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a.  Appropriate thickness. 
b.  Too thick. 
 
c.  Too thin. 
 
Figure 13.  Effects of agar thickness when testing compounds. 
 
 Purchased media with strict quality control criteria was used when performing the 
bacterial testing.  The RMPI media was made in the laboratory.  When pouring the 
molten agar into the petri dishes, approximately 20-30 mL of agar was poured into each 
dish.  However, this volume was estimated and not measured.  This resulted in a variation 
of the media depth and a subsequent difference in zone sizes. 
 
Toxicity Studies 
 
 Once it was determined which compounds had both antibacterial and antifungal 
activity, toxicity studies were performed.  Some methods for performing toxicity testing 
that have been reported include the Sheep Erythrocyte Toxicity Assay and the Brine 
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Shrimp Toxicity Assay.  In the Sheep Erythrocyte assay, toxicity is detected by 
hemolysis of the sheep red blood cells (86).  In the Brine Shrimp assay, toxicity is 
detected and quantitated by the number of brine shrimp that die (76).  For this research, 
compounds were tested to see if they were toxic to human and primate cells.  The cells 
lines used for the toxicity studies included MRC-5, A549, and PMK.  MRC-5 cells are 
derived from human lung fibroblasts and are typically used in a clinical laboratory for the 
cultivation of viruses from the Herpes group, such as Herpes Simplex Virus and 
Cytomegalovirus.  A549 cells are derived from human epithelioid carcinoma and are 
used to detect respiratory viruses.  PMK (or Primary Monkey Kidney) are cells taken 
directly from the kidneys of a sacrificed monkey.  In the clinical laboratory, they are used 
to grow numerous types of viruses (88).  In addition to observing cell lines that were 
inoculated with the test compounds, uninoculated control tubes for each cell line were 
observed to ensure the integrity of the cell line throughout the experiment.   
 Compounds 21 and 35 were tested for toxicity.  Table 15 shows the results of this 
testing. 
 
 Table 15.  Toxicity of compounds that are biologically active against bacteria and yeast. 
 MRC-5 A549 RMK 
Compound 
21 
No toxicity after 24 
hours but slight 
toxicity after 1 week. 
No toxicity after 24 
hours but slight 
toxicity after 1 week 
No toxicity after 24 
hours but slight toxicity 
after 1 week. 
Compound 
35 
Toxicity at 24 hours No toxicity after 24 
hours but slight 
toxicity after 1 week 
Toxicity at 24 hours 
Control 
Tubes 
No toxicity and 
normal appearance 
after 1 week 
No toxicity and normal 
appearance after 1 
week 
No toxicity and normal 
appearance after 1 week 
 
 The toxicity was detected by cytopathic effect (CPE) noted in the cell lines.  
Compound 35 demonstrated severe toxicity in two cell lines after only 24 hours of 
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incubation.  The CPE noted was total destruction of the cell monolayer with few 
remaining cells.  Compound 21 demonstrated slight toxicity after one week of incubation.  
The CPE that was evident included rounding of some of the cells and some holes in the 
monolayer of cells.  However, the cell monolayers were still intact.  This indicated that 
though toxicity was present, it may not have been severe enough to kill the cells.  Figure 
14 shows the extent of cytopathic effect seen in the MRC-5 cells.  Since the control tubes 
appeared normal throughout the length of incubation, the CPE was attributed to the 
toxicity of the compounds being testing and not degradation of the cell lines.   
 
  
 a.  Normal – No Toxicity b.  Slight-Moderate Toxicity  
 
 
 
 
 c.  Severe Toxicity  
Figure 14.  Toxicity seen for compound 21 on MRC-5 cells used in toxicity studies.  a)  
Normal elongated fibroblasts.  b)  Slight toxicity demonstrating holes in the monolayer 
and rounding of some cells.  c)  Severe toxicity showing disintegration of the monolayer.   
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DISCUSSION 
 
Chemical Compounds 
 
 The goal of this research was to use combinatorial chemistry to produce 
compounds that have both antibacterial and antifungal activity.  The notion that agents 
may have both antibacterial and antifungal is not a new idea.  Several agents have been 
described that exhibit activity against both groups of organisms.  These include 
chandrananimycin, bonactin, and sulfonamides (74,75,76).  However, none of these 
products were produced using combinatorial chemistry. 
 When making libraries of chemical compounds, molecules with structures similar 
to mefloquine (an antimalarial drug) were targeted.  (Figure 15)  The focus was on this 
drug because a study performed by Kunin, et al, tested a library of mefloquine-like 
compounds and found that some of the compounds had both antibacterial and antifungal 
activity (77).   
 
  
 Figure 15.  Structure of Mefloquine (77).  
 
 Various methodologies of solid-phase synthesis were considered when making 
the library.  However, the “catch and release” method was the most attractive because it 
NF3C CF3
HO
HN
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required minimal purification of the final products.  This method was used to make the 
amides and sulfonamides.  The chemical constituents attached to the Wang resins were 
chosen based upon the cost of the constituents.   
 Libraries of hydantoins, amides, and sulfonamides were desired because of the 
biological activity of these groups of compounds.  (See Figure 16 for molecular structure 
of hydantoins, amides, sulfonamides.)  Hydantoins are a particularly important class of 
organic compounds because their five membered rings can be substituted to provide a 
great deal of variability.  Derivatives of hydantoins have been identified as having 
antiviral, antibacterial, antifungal, herbicidal, anticonvulsant, antidiabetic, anti-
inflammatory, and anti-ulcer activity (78).  A number of amides and sulfonamides have 
been shown to exhibit antibacterial and/or antifungal activity.  Some of these agents 
include cilofungin, novobiocin, nitazoxanide, sulfamethoxazole and a new drug for the 
treatment of Helicobacter pylori infections known as BAS-118 (79,80,81,82,83). 
 
 
 
 
 
Hydantoin Amide Sulfonamide 
 
Figure 16.  Structures of hydantoins, amides, and sulfonamides (64). 
 
 
Test System for Biological Activity 
 
 A number of methods have been described for detecting biological activity.  
Kleymann, et al, described a method in which the viability of Chinese hamster cells was 
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determined using fluorescein diacetate vital inclusion stain (84).  In this method, cells 
were placed in a microwell tray and were infected with bacteria or fungi in the presence 
or absence of an antimicrobial agent.  After incubation the viability of the cells was 
determined.  The premise behind this approach is that infected cells will die and not take 
up the fluorescent dye.  However, if the compound being tested is added to the cells and 
kills the infecting organism, the cells will remain viable and take up the dye.  The amount 
of dye taken up is measured using spectrophotometry.  The number of viable cells is 
proportional to the level of the fluorescent measurement. 
 Another type of bioassay was described by Ng, et al (85).  In this assay, bacteria 
were inoculated to tubes of Mueller Hinton broth.  Antimicrobial compounds were also 
added to the tubes and then they were incubated at 37oC for 24 hours.  The amount of 
growth or lack of growth was determined by measuring the optical density (OD) of the 
tube.  If the compound added to the tube was active against the organism, the OD of the 
tube was lower than the OD of the bacterial growth control tube. 
 A method similar to the Kirby-Bauer method, known as the agar well diffusion 
method, was described by Aqil, et al (86).  In this method, wells were punched in plates 
of Mueller Hinton agar.  Test organisms were inoculated to the agar as described in this 
research.  Test compounds were then added to the wells and incubated.  The compounds 
diffused through the agar in a similar manner as described in the Kirby-Bauer method.  
Zones of growth inhibition were measured. 
 Although the methods described above would have been acceptable methods for 
determining bioactivity, in this research, a Kirby-Bauer-like method, employing a solid 
medium and looking for visible inhibition of growth, was used.  A very small quantity of 
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each compound was available for testing.  The Kirby-Bauer-like method required a very 
small amount of each compound while the other methods described would have required 
a larger amount.  In addition, the supplies for the Kirby-Bauer-like method were readily 
available in the laboratory. 
 
Toxiticity Testing 
 
 When performing toxicity testing, morphological changes occurred in the cells 
that indicated that toxicity was present.  Compound 35 caused total destruction of the 
cells while compound 21 exhibited slight cellular changes.  It was obvious that compound 
35 caused cell death, but it was not known if the morphological changes caused by 
compound 21 resulted in cell death.  Since only slight cytotoxic effects were seen, it was 
possible that the cells were still viable.  Although viability of cells was not determined in 
this research, it would have been beneficial to make this determination to assess the 
potential for developing the compound into a marketable antimicrobial agent.  The 
usefulness of an antimicrobial agent that causes cytotoxic activity while maintaining 
viability of the cells would be much greater than an antimicrobial agent that causes cell 
death.  Vital stains, such as trypan blue, erythrosine B, and fluorescein diacetate may be 
used to establish viability of cells (103).  Trypan blue and erythrosine B are vital 
exclusion stains while fluorescein diacetate is a vital inclusion stain.  Exclusion stains 
mark only dead cells that have lost membrane integrity.  Inclusion stains color vital cells 
that retain membrane integrity. 
 In this research, MRC-5, A549, and PMK cell lines were used for toxicity testing 
because they were readily assessable in the laboratory.  However, it would have been 
prudent to broaden the extent of testing by using additional cell lines.  In particular, renal 
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and hepatic cells might have allowed detection of toxicity to the kidneys and liver.  Since 
nearly all antimicrobial agents are either excreted by the kidneys or metabolized by the 
liver, drugs tend to exist in high concentrations in these organs and are the sight of 
toxicity in some current antimicrobial agents.  The use of other cells lines could also 
allow detection of organ-specific toxicity if it was noted that toxicity was seen in some 
types of cells and not in others.    
 Although using tissue culture cells in a laboratory setting may give an indication 
of whether toxicity is present or not, there are limitations to using this method.  A number 
of factors may affect the ability to detect toxicity.  These include age of the cell 
monolayer, testing temperature, and mechanical stress from the rotating drum used to 
incubate cells.  In addition, some substances that are not generally considered toxic may 
cause toxicity in human and monkey cell lines.  For example, human blood cells and 
urine may cause toxicity to these cells.  Another complicating factor is that many cells 
that are available for testing from cell-line vendors are immortal cell lines (i.e., cancer 
cells).  These cells are abnormal and may not react the same as normal cells in the human 
body.  As a result, further testing is required to obtain a more definitive indication of the 
presence of toxicity.  Toxicity testing in an animal model is superior to testing in cell 
culture because it allows the detection of toxicity in a living organism.  This simulates the 
environment in which the compound would be used and allows long term toxicity testing 
to be performed. 
 
Biological Activity of Compounds 
 
 The two compounds in this research with both antibacterial and antifungal activity 
were members of the amide and sulfonamide groups and had similar chemical structures 
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(See Table 12).  Due to the presence of a benzene ring in each compound, they were 
more specifically identified as a benzamide and a benzenesulfonamide.  Since the 
mechanism of action for these compounds was unknown, it was speculated that the 
molecular activity may be elucidated by evaluating the properties of similar compounds.  
A literature review identified the mechanism of action for a number of benzamides, 
sulfonamides, and benzenesulfonamides with antimicrobial activity.  The results of this 
review are found in Table 16.   
 
Table 16.  Antimicrobial Activity of Benzamides, Sulfonamides, and             
      Benzenesulfonamides 
Compound Group Biological Activity 
Benzamides • Inhibits DNA gyrase and topoisomerase activity (82) 
• Inactivates glucan synthesis, prohibiting the production of a 
fungal cell wall (81) 
• Interferes with anaerobic metabolism (89) 
• Prohibits cell division by inhibiting post-translational 
regulation of genes (90) 
Sulfonamides • Inhibits folic acid synthesis, interfering with production of 
nucleotides and amino acids (91) 
Benzenesulfonamides • Inhibits topoisomerase activity (92) 
 
 In addition, a literature search looking for the possible cytotoxic effects of 
benzamides, sulfonamides, and benzenesulfonamides in mammalian cells was performed.  
The results of this review are found in Table 17. 
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Table 17.  Activity of Benzamides, Sulfonamides, and Benzenesulfonamides in   
      Mammalian Cells 
Compound Group Biological Activity 
Benzamides • Inhibits DNA repair and synthesis (93) 
• Induces apoptosis (94,95) 
• Inhibits protein kinases (96) 
Sulfonamides • Effects acid-base balance in blood by inhibiting carbonic 
anhydrase (97) 
• Acts as an antagonist of folic acid (91) 
Benzenesulfonamides • Represses transcription and gene expression (98,99) 
• Interferes with prostaglandin production (100) 
• Antagonist of β-3-adrenergic receptor which is responsible 
for “fight-or-flight” response (101) 
• Antagonist to vasoconstrictor (102) 
 
 These results demonstrate that numerous types of biological activity are exhibited 
by benzamides, sulfonamides, and benzenesulfonamides.   Another literature search was 
done in an attempt to further refine the results of the original search.  Since each 
compound had an eight-carbon chain attached to the amide and sulfonamide, a search for 
the biological activity of octylbenzamide and octylbenzenesulfonamide was performed.  
This search yielded no information.  As a result, it is impossible to speculate the exact 
mode of antimicrobial or cytotoxic activity.  Further testing would be required to make 
this determination.   
 
Limiting Factor 
 
 Two limiting factors in this study were the small amount of each of the 
compounds that was received and the lack of purity data.  The small quantity received 
prevented the performance of an adequate number of repeat tests.  It also prevented 
additional studies that would have allowed further characterization of the compounds.  
For example, if more sample of known purity had been available, additional testing 
would have been performed to quantify the level of antimicrobial activity and cytotoxic 
 
69  
effects.  It would have been possible to determine the minimum concentration of the 
compounds that inhibited each organism and the minimum concentration that caused 
cytotoxicity.  If the concentration required for microbial inhibition was greater than the 
concentration required for cytotoxicity, the compound would not have been a useful drug.  
Toxicity would have occurred before an adequate concentration was achieved to inhibit 
the organism.  However, if the concentration required for microbial inhibition was less 
than the concentration required for cytotoxic effect, the compound would still have 
promise as a potential antimicrobial agent. 
 
Conclusion 
 
 The original hypothesis for this research was that combinatorial chemistry may be 
used to produce agents that have both antibacterial and antifungal activity.  This research 
confirmed that it is possible to use combinatorial methods to produce agents with these 
characteristics.  However, the ability to produce antimicrobial compounds is only a small 
part of producing a useful drug.  Other key components of drug discovery, such as 
toxicity studies and the ability to produce the compound in large quantities, are also 
necessary to bring a drug to market and continue the fight against infectious diseases. 
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Appendix A 
 
Table A1.  Supplies 
Item Name Vendor Catalog Number 
Mueller Hinton agar Becton Dickenson B21800 
Mueller Hinton agar with sheep blood  Becton Dickenson B21801 
RMPI 1640 powder Sigma-Aldrich R7755 
Bacto agar Beckton Dickenson DF0140-15-4 
Sterile petri dishes Fisher Scientific 08-757-12 
Sabarouds Dextrose Agar Becton Dickenson B21180 
MOPS buffer Sigma-Aldrich M3183 
Sodium hydroxide solution, 1 molar Fisher Scientific S318-500 
pH paper Cardinal Scientific P1120-8 
Amphotericin Powder Bristol-Myers Squibb NA 
Fluconazole Powder AstraZeneca NA 
Ciprofloxacin Powder Bayer Corporation NA 
Filter paper disk Becton Dickenson 231039 
MLA pipette, 10 μl Fisher 21-381-500 
MLA pipette, 20 μl Cardinal Scientific P5065-20 
MLA pipette, 30 μl Cardinal Scientific P5065-30 
MLA pipette, 100 μl Fisher 21381506 
MLA pipette, 200 μl Fisher 21381507A 
Staphylococcus aureus (ATCC strain 25923) Fisher Scientific 23-021104 
Streptococcus agalactiae Patient isolate NA 
Escherichia coli (ATCC strain 35922) Fisher Scientific 4337015 
Klebsiella oxytoca (ATCC strain 49131) Fisher Scientific 23-021210 
Sterile swab Fisher Scientific 495996C 
TSA agar with 5% sheep blood Becton Dickenson B21261X 
Turbidity meter Dade-Behring B1018-66 
DMSO Sigma-Aldrich D2650 
Crystal violet stain Becton Dickenson B12526 
Disposable pipette tips Cardinal P5048-40 
Cell culture maintenance medium Diagnostic Hybrids RM-02 
MRC-5 cells Diagnostic Hybrids 51-0600 
A549 cells Diagnostic Hybrids 56-0600 
RMK cells Diagnostic Hybrids 49-0600 
Rotating drum Lab Line Instruments Model 1645 
Ethanol, 95% Mallinckrodt 7018-4 
Autoclave Brinkman Model 2540M 
 
 
